Modulation of adaptive immunity by different adjuvant-antigen combinations in mice lacking Nod2.
The mechanisms underlying adjuvant effects are under renewed scrutiny because of the enormous implications for vaccine development. Additionally, new low-toxicity adjuvants are sought to enhance vaccine formulations. Muramyl dipeptide (MDP) is a component of the peptidoglycan polymer and was shown to be an active but low-toxicity component of complete Freund's adjuvant, a powerful adjuvant composed of mycobacteria lysates in an oil emulsion. MDP activates cells primarily via the cytosolic NLR family member Nod2 and is therefore linked to the ability of adjuvants to enhance antibody production. Accordingly, we tested the adjuvant properties of the MDP-Nod2 pathway. We found that MDP, compared to the TLR agonist lipopolysaccharide, has minimal adjuvant properties for antibody production under a variety of immunization conditions. We also observed that the oil emulsion incomplete Freund's adjuvant (IFA) supplanted the requirements for the TLR pathway independent of the antigen. Surprisingly, we observed that Nod2 was required for an optimal IgG1 and IgG2c response in the absence of exogenous TLR or NLR agonists. Collectively, our results argue that oil emulsions deserve greater attention for their immunostimulatory properties.
Moreira
Lilian O
LO
Department of Infectious Diseases, St Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105, USA.
Smith
Amber M
AM
DeFreitas
Ashley A
AA
Qualls
Joseph E
JE
El Kasmi
Karim C
KC
Murray
Peter J
PJ
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000494:pharmacology; D000220:Adaptation, Biological / Q000235:genetics* / Q000276:immunology*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D004655:Emulsions; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005620:Freund's Adjuvant / Q000494:pharmacology; D007109:Immunity / Q000235:genetics* / Q000276:immunology*; D007114:Immunization; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D007274:Injections, Intraperitoneal; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics; D053473:Nod2 Signaling Adaptor Protein / Q000235:genetics* / Q000502:physiology*; D012709:Serum Albumin / Q000276:immunology; D051193:Toll-Like Receptors / Q000235:genetics / Q000276:immunology; D032581:Tuberculosis Vaccines / Q000276:immunology; D014612:Vaccines / Q000008:administration & dosage / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D004655:Emulsions; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008070:Lipopolysaccharides; D053594:Myeloid Differentiation Factor 88; D053473:Nod2 Signaling Adaptor Protein; D012709:Serum Albumin; D051193:Toll-Like Receptors; D032581:Tuberculosis Vaccines; D014612:Vaccines; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D005620:Freund's Adjuvant
J Exp Med. 2008 Apr 14;205(4):869-82
18362170
Mol Cell Biol. 2003 Nov;23(21):7531-9
14560001
Nature. 2007 Jul 26;448(7152):427-34
17653185
J Immunol. 2008 Apr 15;180(8):5402-12
18390722
J Neurochem. 2006 Oct;99(2):596-607
16879708
J Immunol. 2005 Jun 1;174(11):7096-103
15905553
Science. 2007 Jun 15;316(5831):1628-32
17569868
Eur J Immunol. 2008 Aug;38(8):2085-9
18624356
Immunity. 1998 Jul;9(1):143-50
9697844
J Leukoc Biol. 2007 Jul;82(1):177-83
17403772
Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317-25
4606813
N Engl J Med. 1995 May 11;332(19):1280-4
7708073
Vaccine. 1992;10(14):1000-6
1471423
Immunity. 2007 Nov;27(5):687-90
18031690
Mol Cell Biochem. 1981 Dec 4;41:27-47
7035868
Trends Parasitol. 2005 Sep;21(9):412-4
16043410
J Biol Chem. 2002 Oct 18;277(42):39179-86
12151399
Nat Immunol. 2007 Dec;8(12):1269-71
18026075
J Clin Invest. 2007 Mar;117(3):514-21
17332878
Vaccine. 1999 Oct 14;18(5-6):434-9
10519932
Proc Natl Acad Sci U S A. 2008 Jun 3;105(22):7803-8
18511561
Nature. 2006 Mar 9;440(7081):228-32
16407890
Curr Opin Immunol. 2005 Aug;17(4):352-8
15950446
Immunity. 2007 Oct;27(4):549-59
17967410
Mol Cell. 2007 Mar 9;25(5):713-24
17349957
J Immunol. 2008 Jul 1;181(1):17-21
18566365
Clin Pharmacol Ther. 2007 Dec;82(6):740-4
17971820
Curr Biol. 2004 Nov 9;14(21):1929-34
15530394
Nature. 2008 Jun 19;453(7198):1122-6
18496530
Am J Physiol. 1988 Jul;255(1 Pt 2):R157-65
3394839
Nat Rev Immunol. 2008 Jun;8(6):458-66
18500230
Biochem Biophys Res Commun. 1974 Feb 4;56(3):561-7
4597063
J Immunol. 2007 Apr 15;178(8):5271-6
17404311
Nat Rev Immunol. 2006 Jan;6(1):9-20
16493424
J Immunol. 2006 Nov 1;177(9):6182-91
17056547
Infect Immun. 1995 Jan;63(1):110-5
7806345
Nature. 2005 Nov 17;438(7066):364-8
16292312
Behav Brain Res. 1995 Jul-Aug;69(1-2):85-90
7546321
Int J Immunopharmacol. 1979;1(1):35-41
551094
Science. 2005 Feb 4;307(5710):731-4
15692051
Science. 2006 Dec 22;314(5807):1936-8
17185603
Curr Opin Immunol. 2007 Jun;19(3):268-74
17433875
PLoS One. 2007 Jun 13;2(6):e523
17565376
Immunology. 1978 Dec;35(6):963-70
738768